A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants

Inclusion Criteria

• •Male 18 years of age or older
• •Participant with histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate
• •Participant with documented metastatic prostate cancer
• •Participant with documented castration resistance with progression of prostate cancer on androgen deprivation therapy (ADT)
• •Participant who will be initiated on either abiraterone acetate or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that is asymptomatic or mildly symptomatic (per physician's evaluation) after failure of ADT at the time of treatment initiation
• •Participants who signed a participation agreement or Informed consent form (ICF) per local regulations
• •The treatment decision (abiraterone acetate or enzalutamide) by the treating physician must have been taken before enrollment into the study
• •Baseline patient-reported outcomes (PROs) must be captured before the first administration of abiraterone acetate or enzalutamide.